Method for diagnosing and treating bronchial asthma

ABSTRACT

A method for diagnosing and treating a bronchial asthma by classifying a patient&#39;s asthma as Type I, Type II or Type III based on the patient&#39;s symptoms is disclosed. The symptoms for the three types of asthma are disclosed together with recommended treatment guidelines for each type to optimize treatment regiments based on symptoms.

FIELD OF THE INVENTION

This invention relates to a method for diagnosing and treating bronchialasthma and more particularly to a method and treatment based oncategorizing bronchial asthma into three types and optimizing treatmentbased on the type of asthma encountered.

BACKGROUND FOR THE INVENTION

It has been reported that asthma is the number one chronic illness forchildren and is a significant cause of infants' deaths. It has also beenreported that over twenty million Americans have asthma. It addition, itis well known that asthma is adversely affected by pollution. For thisreason, there has been a significant increase in asthma cases in Kuwaitsince the Gulf War and the fire set in the Kuwait oil fields by theretreating Iraqi troops.

Bronchial Asthma typically causes decreased lung function, bronchialinflammation, coughing, wheezing and tightness in the chest. Theseproblems are often exasperated by air born irritants such as smoke,exercise, viral infections etc. When a patient encounters such problems,it means that the individual's airway is obstructed and the lungs arenot receiving sufficient air. Typically, the airways become obstructeddue to the lining of the airways becoming irritated and swollen andbecause the airways tighten causing them to narrow.

With modern medicine, there are many treatments for asthma. However,most of the drugs prescribed have the potential for negative sideeffects. For example, asthma treatment can cause depression, dizziness,fatigue, impotence, liver damage etc. In addition, some medications areeffective for some patients but less effective with others. Therefore,it is highly desirable to select the right treatment for the rightpatient.

The main idea of the new invention is to categorize the patient withBronchial Asthma so you can give the right medication to the rightpatient thereby reducing side effects of the medication.

BRIEF SUMMARY OF THE INVENTION

In essence the present invention contemplates a method for diagnosingand treating a patient with Bronchial Asthma. The method includes thestep of classifying a patient's asthma into three types, namely Type I(a wet type), Type II (a dry type) and Type III (a mixed type). The TypeI asthma is characterized by more production of mucus than broncoconstriction while the dry type has more bronco spasm than mucusproduction. The mixed type is a mixture of the two i.e. Type I and TypeII. A patient is then diagnosed as Type I, Type II or Type III based onan examination of the patient. For Type I, a patient is treated with amucolyptic more than a bronco dilator or with a bronco dilator if TypeII or some combination of the two if Type III.

In a preferred embodiment of the invention, the diagnosis is based onthe onset of symptoms, severity of symptoms at the onset of thesymptoms, chest findings, other allergy symptoms, X-ray findings,trigger factors and to a degree response to treatment and age of thepatient. The treatment for the Type I asthma includes more use of amucolyptic than a broncho dilator, and if a nebulizer is used it shouldinclude Bisolvon®, a bromhexine that is a synthetic derivative ofvasicine. In essence the Bisolvon® is an expectorant i.e. mucus or phlemdissolving preparation. Small doses of a bronco dilator may also be usedto open the passages to let the mucus pass. Cortisone is seldom used forsuch patients.

For those patients with the Type II asthma, they are treated with abronco dilator and/or nebulizer with the addition of Atrovert,adrenaline and pulmicort if needed in measured amounts. This combinationhas given relatively quick response and is often effective in decreasingthe use of a nebulizer. The treatment for Type III includes acombination of the treatments for Types I and II and is derived based onthe physician's experience.

DESCRIPTION OF THE DRAWINGS

FIG. 1 a block diagram illustrating a method for categorizing differenttypes of asthma in accordance with the present invention;

FIG. 2 is a block diagram illustrating a method for treating differenttypes of asthma in accordance with the present invention;

FIG. 3 is a block diagram illustrating a method for diagnosing andtreating asthma in accordance with the present invention; and

FIG. 4 is a block diagram illustrating the method for diagnosing andtreating asthma in accordance with the present invention.

DESCRIPTION OF THE PREFERRED EMBODIMENTS OF THE INVENTION

A diagnostic method and method for treating patients with BronchialAsthma will now be described in connection with FIGS. 1-3. Asillustrated in FIG. 1, a diagnostic method 20 includes a step 22 ofdividing or categorizing asthma into three types i.e. Type I (wet type)as indicated by box 24, Type II (dry type) as indicated by box 26 andType III (mixed type) as indicated by box 28. The division of the threetypes is based on differences in symptoms.

The criteria for diagnosing the different types of asthma were developedbased on the examination and treatment of numerous patients. Thecriteria are based on the age of the patient, the age at initial attack(onset of the presentation) or the severity of the initial attack(s),chest findings, evidence of other symptoms as well as the results of anyprevious treatments tried and used.

Differences in chest findings for the different types of BronchialAsthma are described as follows: Type I (wet type)—chest examinationwill reveal a bubbled sound,

Type II (dry type)—there will be flaring of alae nasi, and usingaccessory muscles of respiration, prolonged expiratory phase and wheezesand in Type III (mixed type), we could find the mixture of symptoms ofboth types.

Evidences of other symptoms are likewise outlined here. In Wet Type I,the baby will usually present with a blocked nose, less likely to haveallergic symptoms and cough throughout the day. In Dry Type II, thechild will be very distress, manifesting allergic symptoms like allergicrhinitis, eczema which may precede or come later and continuous coughthroughout the day but usually more severe during the night.

To expound further on the result of any previous treatment tried andused, it is understood that Bronchial Asthma was not recognized beforeas a heterogenous disease thus it was treated as only one disease usingcough syrup and a bronchodilator. Although some authors were againstgiving mucolytics, some others were giving mucolytics because it was notclear to them that Bronchial Asthma is not just one disease. As somewere against, others may be giving mucolytic with a bronchodilator. Mostof available medications for treatment of Bronchial Asthma isrecategorize according to the types of Bronchial Asthma and this givesgood results because the right treatment id given to the right patient.

Before the new invention, all kinds of bronchial asthma were treated thesame and it is divided into its Acute Stages:

During Acute Stage:

-   -   For a child in acute stage:        -   1. mostly nebulizer            -   Bronchodilator—mainly Ventolin (6) and Atrovent (3) use                of mucolytic like Bisolvon (1) was controversial.            -   Inhaled Steroid—less likely to be used, its used mainly                as a prophylaxis.        -   2. Injected Steroid—can be used if the case needed.        -   3. Some authors add IV aminophylline (7) which is not            currently recommended.        -   4. Once the Acute Stage passes they gave:            -   Bronchodilator like Ventolin (6) syrup or Bricanyl (8)                or Berotec (9) and some used oral cortisone.

As Prophylaxis:

This is decided according to severity, age of patient and availablemedication

-   -   1. Either Pulmicort (5) or Flixotide (10) inhaler (inhaled        steroid)    -   2. Singular (1)—either sachet 4 mg or 4-5 mg label

These were what were used to be given before for all children withBronchial Asthma but with the new invention:

The Wet Type:

During Acute Stage:

-   -   Need more mucolytic to dissolve the mucus like Bisolvon (1) and        you can add bronchodilator to help open the closed bronchioles    -   If you do so you will not need to use cortisone either inhaled        or injectable. When the Acute Stage subsides, I will give any        mucolytic like Mucosolvan (12) and Prospan (13) to dissolve the        sputum which will give dramatic and marvelous result. This group        of patient since you treated the cause they're less likely to        get prophylaxis

The Dry Type:

During Acute Stage:

-   -   Inhalation: Use Ventolin (6) Nebulization Solution,        Adrenalin (4) and inhaled Steroid like Pulmicort (5) No need for        inhaled mucolytic    -   Some need to be given injectable steroids and they gave dramatic        response    -   Once patient's acute stage subsides, I will give cough syrup and        bronchodilator like Bricanyl (8) +/−oral cortisone (2)    -   This group of patient may need prophylaxis either inhaled        steroid or singular

In addition to the above X-ray findings, trigger factors and responsesto further treatment are considered. The following are the usual x-rayfindings:

-   -   In Wet Type:—the x-ray will be hazy, white lung    -   In Dry Type:—signs of hyperinflation, and a dark lung

The Type I asthma sometimes referred to as the Wet Type and is typicallycharacterized by the following symptoms as indicated by box 32. Thesymptoms include the age of the patient. For example, Type I asthma istypically found in younger patients from 0 to 1 year old. The type Iasthma is also characterized by less distress during an attack(presentation) and chest findings that show bubbled lungs, few wheezesduring an attack and lack of allergic symptoms. Additional symptomsinclude the finding that the patient rarely need prophylactics likeSingular (11) if needed and their x-rays show a hazy white lung field.Further, there are no clear triggering factors and the patient usuallyshows a relatively quick response to proper treatment for Type I asthma.

The symptoms for Type II asthma are typically found in an older agegroup i.e. those are usually from 1 to 5 years of age but can also occurlater on and are further characterized by prolonged expiratory phasesand lots of wheezes. Additional symptoms of the Type II asthma relate tothe use of accessory muscles for breathing and evidence of otherallergies.

A number of patients that exhibit evidence of both Type I and Type IIasthma are categorized as Type III i.e. a Mixed Type of asthma. Unlesspatients' symptoms that are predominantly categorized as Type I or TypeII they are classified as a Type III or mixed type asthmatic. Usuallythe following symptoms occur for the Dry Type II patients; severedistress on presentation, flaring alae nasi, using accessory muscles ofrespiration, with or without cyanosis, inability to continue thesentences spoken, cough mainly at night, runny nose and could bepreceded by a viral infection, exercise and they could also have eczema.

Having characterized the types of asthma and the symptoms of each type,a physician is better prepared to examine and treat a patient, which isdefined as a treatment method 40. In the treatment method 40, aphysician reviews a patient's medical history and examines the patientand conducts a conventional examination of the patient in step 42. Afterexamining the patient, the physician characterizes the patient's asthmaas Type I in box 44, Type II in box 46 or Type III as indicated by box48. After characterizing the type of asthma experienced by the patientin boxes 44, 46 and 48, the physician considers the appropriatetreatment as set forth in boxes 50, 52 and 54 and prescribes anappropriate regime for the patient as indicated by box 56.

The treatment for Type I Asthma includes the use of mucolytic such asMucosolvan (12), Prospan (13), Bisolvon (1) and Tuscalman (14) more sothan bronchodilators. Bronchodilators which acts as mainstay onnebulization are Ventolin (6) and Atrovent (3). In those cases where anebulizer is called for, an addition of Bisolvon (I) (bromhexine or itsequivalent) to dissolve the mucus may be added based on the physician'sexperience. The physician may also add small doses of a bronchodilatorsuch as Atrovent (3) and Ventolin (6) to let the mildly constrictedairways open up and let the mucus pass. In Type I asthma, cortisone israrely used as re prophylactics.

Hypothetical Patient Type I

-   -   Mariam is 2 months of age with weight of 5.4 kg, height 52 cm        and presented with cough, noisy breathing and blocked nose for        the last 3 days after her father smoke cigarettes near the baby.        She was afebrile, mildly distress on examination, no cyanosis,        respiratory rales is mildly distress and no dysmorphic feature.

Mouth: oral trash Ear: no abnormality detected Nose: blocked Chest:bubbled lung, no wheezes Abdomen: intact CVS: intact CNS: intact

Baby was diagnosed to have Bronchial Asthma Type I. She was given thefollowing treatment:

-   -   Tuscalman (14)    -   Prospan drops (13)

The treatment of Type II asthma typically includes the use of abronchodilator as a cornerstone of treatment. Such bronchodilators maybe administered orally but mostly by nebulizers particularly in an acutestage. These bronchodilators are given either thru nebulization such asAtrovent (3), Ventolin (6) or Adrenalin (4) or as orally using Bricanyl(8), Berotec (9) or Ventolin (6). Cortisones may also be used throughinhalation using Pulmicort (5) and oral steroid such as Decadron (2).Prophylactics used for this type are inhaled steroid and Singular (11).

An example of a Hypothetical patient having Type II asthma and theirtreatment follows:

Hypothetical Case, Type II

Mosa is a 5 year old boy, he was presented to my clinic with distress,severe cough that he could not sleep last night after he was exposed toa sandstorm. Last night, the child is restless with flaring alae nasi,using his accessory muscles or respiration, mildly cyanotic, afebrile,HR (100/min), high RR and a congested throat

Chest

-   -   prolonged expiratory phase    -   a lot of wheezes

Others

-   -   system intact

He was given hydrocortisone injection with a dose of 50 mg newnebulization are Atrovent (3) and Pulmicort (5) with Adrenalin (4). Hewas diagnosed to have attacks of Bronchial Asthma, Type II (Dry Type) hewas given cough syrup.

Bronchodilator in nebulization for 2-3 days followed by oralBronchodilator like Bricanyl (8) or Berotec (9) and cortisone (Decadron)(2). This boy used to have a frequent attacks of Bronchial Asthma. Lastattack was before 2 weeks so he needs to take prophylaxis like Singular(11) tablets or Pulmicort (5) nebulization solution according to thediscussion with the mother.

The treatment of Type III asthma presents a greater challenge to thephysician. With symptoms of Type I and Type II asthma present, it isnecessary to use a balance treatments from each type and find atreatment that fits the need of a specific patient. For example, atreatment of a hypothetical patient based on a compilation of studies ofpatients with Type III asthma is as follows:

Hypothetical Case Type III

Mohesen is 1.2 month old boy who was presented with a cough and runningnose for one week. Clinical presentation mild to moderate distress,afebrile, chest findings is a mix of bubble lung and wheezes. He took 2doses of nebulization (Atrovent (3), Ventolin (6)) and continued abronchodilator and cough syrup like Sinecod (15).

The practice of a preferred embodiment of the present invention will nowbe described in connection with FIG. 3. As shown in FIG. 3, a physiciancharacterizes the three types of asthma as indicated in box 60 based onthe symptoms for each of the three types as indicated in box 62. Thephysician also identifies the treatment which were generally mosteffective for each of the three types of asthma as indicated by box 64.As indicated by box 66, with the above mental background, the physicianconducts a conventional examination of a patient including review of thepatient's medical history and prescribes an appropriate treatment asindicated by box 68. Following this, the physician follows up on theresults of the treatment as indicated in box 70 and if necessarymodifies the treatment.

Drug Index 1. Bisolvon (Bromhexine Hydrochloride)—

-   -   Mucolytics    -   Concentration: 4 mg/2 ml for inhalation and oral administration        containing 8 mg    -   Bromhexine is a synthetic derivative of a herbal active        ingredient vasicine    -   Enhances mucous transport by reducing mucous viscosity,        mucociliary clearance    -   Doses:        -   Children 6-12:            -   1 ml 2 times daily            -   2-6: 10 drops 2 times daily            -   <2.yo: 5 drops 2 times daily            -   But usually we add 2-3 drops which is more than enough

2. Decadron (Dexamethasone)

-   -   A synthetic glucocorticoid used for its anti-inflammatory        effects    -   It has 25 to 30 times the anti-inflammatory activity of        hydrocortisone    -   0.5 mg tablet: blister pack of 30's, 0.5 mg/5 ml: bottle of 100        ml as elixir        -   Doses: In acute, self-limited allergic disorders or acute            exacerbations of chronic allergic disorders (e.g. bronchial            asthma)            -   Dosage requirements are variable and must be                individualized according to the severity of the disease                and the response of the patient            -   The usual initial dosage varies from 0.75 to 15 mg a day                depending on the disease being treated            -   For infants and children, the recommended doses usually                will have to be reduced, but dosage should be dictated                by the severity of the condition rather than by age or                body weight.)

3. Atrovent (Ipatropium Bromide)

-   -   Anti muscarinic bronchodilator    -   Doses of child: 100-500 microgram (0.4-2 ml at 0.02% solution)    -   1 ml (20 drops) 0.025% solution for inhalation with nebulising        devices contain: 261 mcgg (=1 ipatropium bromide) corresponding        to 250 mg ipatropium bromide anhydrose bronchodilator    -   Doses        -   6-12 years old: 1 ml (20 drops=0.25 ml) 3 to 4 times daily        -   <6 y.o.: 0-0.4-1 ml (8-20 drops=0.1-0.25 mg) 3 to 4 times            daily

4. Adrenalin

5. Pulmicort nebulizer solution (budesonide)

-   -   Concentration: 0.25 mg/ml-0.5 mg/ml    -   Budesonide is a gluco corticosteroid with a high local anti        inflammatory effect to prevent the release of inflammatory        mediator    -   Studies have shown that the earlier budesonide treatment is        initiated after the onset of asthma, the better lung function        can be expected    -   Doses:        -   Acute: from 6 months: 0.25-0.5 mg per day, may increase up            to 1 mg/day        -   Prophylaxis: from 6 months: 0.25-2 mg/day

6. Ventolin Respiratory Solution

-   -   Provide 5 mg/ml of salbutamol sulphate of nebulization    -   It is selective Beta 2 agonist that provides short acting        (4-6 ml) bronchodilator with fast onset (5 minutes)    -   Dose in children under the age of 12 years old        -   Minimum: 0.5 ml (2.5 mg of salbutamol) diluted to 2-2.5 ml            with normal saline        -   However, higher dose of up to 5 mg could be used

7. Aminophylline— 8. Bricanyl (Terbutaline Sulphate)

-   -   1 ml contains Terbutaline sulphate 0.3 mg    -   Should be used as a maintenance therapy in asthma and other        pulmonary diseases where bronchospasm is a complicating factor    -   Doses:        -   Children: 0.075 mg (0.25 ml)/kg Body weight 3 times daily

Suitable Doses: (Kg) Dosage 4 1 ml × 3 6 1.5 ml × 3   8 2 ml × 3 10 2.5ml × 3   12 3 ml × 3 14 3.5 ml × 3   16 4 ml × 3 18 4.5 ml × 3   20 5 ml× 3 24 6 ml × 3 28 7 ml × 3 32 8 ml × 3 36 9 ml × 3 40 10 ml × 3 

If an adequate response is not obtained with this dose, the dose may bedoubled, provided adverse reactions are not pronounced

9. Berotec

-   -   Bronchodilator    -   2.5 mg tablet, liquid 2.5 mg 5 ml    -   1 teaspoonful liquid contains        1-(3,5-dihydroxyphenyl)-2-hydroxy-benzyl)-ethyl-amino athanol        hydrobromide (=fenoterol hydrobromide)    -   Doses:        -   Infants up to 1 y.o.—(below 10 kg BW)=2.5 ml liquid 2 to 3            times daily        -   Children 1-6 y.o—(ca. 10-22 kg BW)=0.5-1 tablet/2.5-5 ml            liquid 3× daily        -   Children 6-14 y.o.—=1 tablet or 5 ml liquid 3 times daily

10. Flixotide Evohaler 125 mcg

-   -   Fllixotide Evohaler is a pressurized inhalation, suspension        delivering 125 micrograms of fluticasone propionate per        actuation    -   Given by inhalation offers prophylactic treatment of asthma    -   Doses:        -   Mild Asthma:—100 to 250 mcgs twice daily        -   Moderate Asthma:—250 to 500 mcgs twice daily        -   Severe Asthma:—500 to 1,000 mcgs twice daily            -   Administration of doses>1000 mcgs (500 mcgs twice daily)                should be via spacer device to help reduce side-effects                in the mouth and throat

The dose should be titrated to the lowest dose t which effective controlof asthma is maintained

It should be taken regularly even when asymptomatic. Onset oftherapeutic effect is within 4 to 7 days

11. Singular (Montelukast Sodium)

-   -   4 mg sachet, 4 mg, 5 mg chewable tablet    -   It is a leukotriene receptor antagonist so it blocks the        receptos of leukotriene (naturally occurring chemicals that        cause narrowing of the airway and inflammation)    -   Doses:        -   From 6 months-5 years=4 mg either sachet or chewable tablet        -   From 6-12 years=5 mg once daily or at bedtime

12. Mucosolvan

-   -   Preclinically, ambroxol, the active ingredianet of Mucosolvan,        has been shown to increase respiratory tract secretion. It        enhances pulmonary surfactant production and stimulate ciliary        activity    -   liquid 15 mg/5 ml, solution for oral or inhalation use 15 mg/2        ml    -   Doses:        -   Liquid 15 mg/5 ml            -   <2 y. o.—2.5 ml (½ teaspoon) 2 times daily            -   2-6 y.o.—2.5 ml (½ teaspoon) 3 times daily            -   6-12 y.o.—5 ml (1 teaspoon) 2-3 times daily        -   Solution 15 mg/2 ml for oral and inhalation use            -   <2 y. o.—1 ml (=25 drops) 2 times daily            -   2-6 y.o.—1 ml (=25 drops) 3 times daily            -   >6 y.o.—2 ml (=50 drops) 2-3 times daily

13. Prospan (Herbal Drops)

-   -   Mucolytic, spasmolytic, cough relieving    -   100 ml bottle    -   Composition: 100 ml solution contains 2 g of dried ivy leaf        extract (5-7.5:1); extractive agent: ethanol 30% (w/w):Herbal        Drops contains 47% vol. alcohol    -   Herbal Drops is a natural product and contains an active        ingredient.        -   which is purely herbal    -   Doses:        -   Infants—10 to 15 drops 3 to 5 times daily        -   Small children—15 drops 3 to 5 times daily        -   Adults and schoolchildren—20 drops 3 to 5 times daily

14. Tuscalman

-   -   Antitussive    -   Tuscalman contains noscapine as the effective principle. This        substance exerts a reliable, suppressive action on the cough        center    -   Drops:        -   15 mg Noscapini Hydrochloridium, 100 mg Guaifenesinum        -   Syrup: 15 mg, 100 mg, 250 mg        -   Suppositories: 10 mg, 50 mg    -   Packings: 20 ml dropper-bottle, 120 ml bottle,        -   Suppositories A and B=boxes of 10 suppositories    -   Doses:        -   Drops for Children—10-20 drops for 2 to 3 times daily        -   Syrup: 6-12 y.o.—1 teaspoonful 3 to 5 times daily        -   Suppositories A:            -   —0-8 months 2 suppositories daily            -   9-18 months 3 suppositories daily        -   Suppositories B:—1.5 to 3 y.o—2 suppositories daily            -   4-8 y.o.—3 to 4 suppositories daily

15. Sinecod

-   -   Antitussive    -   Active Principle: Butamirate citrate, a central cough        suppressant which is chemically and pharmacologically unrelated        to the opium alkaloids. It reduce airway resistance    -   Drops for children: pack of 20 ml, syrup: pack of 200 ml    -   Doses:        -   Drops for Children:            -   2 months—1 year—10 drops 4 times daily            -   1-3 y.o.—15 drops 4 times daily            -   <3 y.o.—25 drops 4 times daily        -   Syrup:            -   3 to 6 y.o.—5 ml 3 times daily            -   6 to 12 y.o.—10 ml 3 times daily

While the invention has been described in connection with its preferredembodiment it should be recognized that changes and modifications can bemade therein without departing from the scope of the appended claims.

1. A method for diagnosing and treating a patient with bronchial asthmacomprising the steps of: establishing three types of bronchial asthma,namely Type I or a wet type, Type II or a dry type and Type III or amixed type and wherein the wet type is characterized by more productionof mucus than bronchi constriction while the dry type presents moreevidence of bronchi spasms than mucus production and Type III, the mixedtype is between the Type I and Type II asthmas; diagnosing a patientsasthma as a Type I, Type II or Type III asthma based on an examinationof a patient; and treating the patient for the type of asthma diagnosedwherein the Type I asthma is treated with a mucolytic more than a broncodilator and in which the Type II is treated with a bronco dilator as amajor part of the treatment.
 2. A method for diagnosing and treating apatient with bronchial asthma according to claim 1 in which thediagnoses of a patient's asthma is based on an initial physicalexamination.
 3. A method for diagnosing and treating a patient withbronchial asthma according to claim 2 in which the diagnoses is alsobased on a patient's age.
 4. A method for diagnosing and treating apatient with bronchial asthma according to claim 3 in which thediagnoses is also based on the severity of the symptoms during aninitial attack.
 5. A method for diagnosing and treating a patient withbronchial asthma according to claim 4 in which the diagnoses is alsobased on chest findings.
 6. A method for diagnosing and treating apatient with bronchial asthma according to claim 5 in which thediagnoses is also based on a presentation of other allergies symptoms.7. A method for diagnosing and treating a patient with bronchial asthmaaccording to claim 6 in which the diagnoses is also based on X-rayfindings.
 8. A method for diagnosing and treating a patient withbronchial asthma according to claim 7 in which the diagnosis is alsobased on triggering factors.
 9. A method for diagnosing and treating apatient with bronchial asthma according to claim 8 in which thediagnoses is also based on a patient's response to treatment.
 10. Amethod for diagnosing and treating a patient with bronchial asthmaaccording to claim 1 in which the criteria for diagnoses includes theage at onset; the severity at onset; chest findings; other allergicsymptoms; treatments used namely medication used, use of nebulizers ororal bronco dilators, use of cortisone and need for prophylactics, X-rayfindings, triggering factors, responses to treatment and wherein adiagnoses of the Type I or Type II of asthma is also based on the age ofthe patient.
 11. A method for diagnosing and treating a patient withbronchial asthma according to claim 10 wherein the diagnoses of a Type Iasthma is based on chest findings and bubbled lungs and wheezes.
 12. Amethod for diagnosing and treating a patient with bronchial asthmaaccording to claim 1 in which the diagnoses of a Type II asthma is basedon a lot of wheezes and an X-ray showing hyperinflation and a dark lung.13. A method for diagnosing and treating a patient with bronchial asthmaaccording to claim 11 which includes the step of treating the patientwith a mucus dissolving agent and a mild bronco dilator.
 14. A methodfor diagnosing and treating a patient with bronchial asthma according toclaim 13 which includes the step of: prescribing a nebulizer with anaddition of a synthetic derivative of vasicine to dissolve the mucus.15. A method for diagnosing and treating a patient with bronchial asthmaaccording to claim 12 which includes the step of treating the patientwith Atrovert®, Adrenalin (4) and Pulmicort (5).